Onyx Biotec Limited, founded in 2005, is a pharmaceutical manufacturer specializing in sterile water for injections, dry powder injections, and dry syrup, catering to both Indian and global markets.

The company boasts robust manufacturing capabilities with two manufacturing units in Solan, Himachal Pradesh, offering a combined capacity of over 230 million units annually.

A significant capacity expansion was achieved in 2017-18, followed by the commencement of Unit II's commercial production in 2023, boosting their production capabilities.

Onyx is preparing for an IPO with the issuance of 48,10,000 fresh equity shares, indicating growth ambitions in capital markets.

Their core service offering includes end-to-end product development and regulatory dossier preparation for pharmaceutical clients, positioning Onyx as a comprehensive contract manufacturing partner.